Progress and challenges in the discovery of macrofilaricidal drugs

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 681-695

  Geary, Timothy G ^a   MacKenzie, Charles D ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

anthelmintic; filarial; flubendazole; lymphatic filariasis; macrocyclic lactone; nematode; onchocerciasis

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIFILARIAL AGENT; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CYCLO(DEXTRO LACTYL N METHYLLEUCYL DEXTRO 3 PHENYLLACTYL N METHYLLEUCYL DEXTRO LACTYL N METHYLLEUCYL DEXTRO 3 PHENYLLACTYL N METHYLLEUCYL); CYCLODEPSIPEPTIDE; DERQUANTEL; DIETHYLCARBAMAZINE; DOXYCYCLINE; EMODEPSIDE; FLUBENDAZOLE; IVERMECTIN; MEBENDAZOLE; MELARSAMINE; MONEPANTEL; MOXIDECTIN; NITAZOXANIDE; OXFENDAZOLE; SURAMIN; TIABENDAZOLE; TRIBENDIMIDINE; UMF 078; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANTHELMINTIC ACTIVITY; CESTODIASIS; CLINICAL EFFECTIVENESS; DIROFILARIASIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; ERADICATION THERAPY; FETOTOXICITY; FILARIASIS; GASTROINTESTINAL INFECTION; HELMINTHIASIS; HUMAN; LYMPHATIC FILARIASIS; NEMATODIASIS; NEUROCYSTICERCOSIS; NEUROTOXICITY; NONHUMAN; ONCHOCERCIASIS; PARASITE CONTROL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANIMALS; BRUGIA; DOXYCYCLINE; DRUG DISCOVERY; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; LACTONES; MACROCYCLIC COMPOUNDS; MACROLIDES; MICROFILARIA; ONCHOCERCA; ONCHOCERCIASIS; WUCHERERIA BANCROFTI;

EID: 80051775550     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.76     Document Type: Review

References (99)

1. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The Global Programme to Eliminate Lymphatic Filariasis: Health impact after 8 years. PLoS Negl. Trop. Dis. 2, e317 (2008).
2. Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv. Parasitol. 61, 349-394 (2006). (Pubitemid 43792518)
3. Thylefors B. The Mectizan Donation Program. Ann. Trop. Med. Parasitol. 102(Suppl. 1), 39-44 (2008).
4. McCall JW, Genchi C, Kramer LH, Guerrero J, Venco L. Heartworm disease in animals and humans. Adv. Parasitol. 66, 193-285 (2008).
5. Bowman DD, Atkins CE. Heartworm biology, treatment and control. Vet. Clin. North Am. Small Animal Pract. 39, 1127-1158 (2009).
6. Geary TG. Ivermectin 20 years on: Maturation of a wonder drug. Trends Parasitol. 21, 530-532 (2005). (Pubitemid 41447026)
7. Schaeffer JM, Haines HW. Avermectin binding in Caenorhabditis elegans. A two-state model for the avermectin binding site. Biochem. Pharmacol. 38, 2329-2338 (1989). 8 Cheeseman CL, Delany NS, Woods DJ, Wolstenholme AJ. High-affinity ivermectin binding to recombinant subunits of the Haemonchus contortus glutamate-gated chloride channel. Mol. Biochem. Parasitol. 114(2), 161-168 (2001).
8. Cheeseman CL, Delany NS, Woods DJ, Wolstenholme AJ. High-affinity ivermectin binding to recombinant subunits of the Haemonchus contortus glutamate-gated chloride channel. Mol. Biochem. Parasitol. 114(2), 161-168 (2001) (Pubitemid 32510753)
9. Geary TG, Moreno Y. Macrocyclic lactone anthelmintics: Spectrum of activity and mechanism of action. Curr. Pharmaceut. Biotech. (2011) (In Press).
10. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the Eradicability of Onchocerciasis. Filaria J. 2, 2 (2003).
11. Bockarie MJ, Deb RM. Elimination of lymphatic filariasis: Do we have the drugs to complete the job? Curr. Opin. Infect. Dis. 23, 617-620 (2010).
12. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: History of progress and current feasibility using ivermectin (Mectizan) monotherapy. Acta Trop. DOI: 10.1016/j.actatropica.2010.08.009 (2010) (Epub ahead of print).
13. Maizels RM, Denham DA. Diethylcarbamazine (DEC): Immunopharmacological interactions of an anti-filarial drug. Parasitology 105(Suppl.), S49-S60 (1992). (Pubitemid 23233503)
14. Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2(Suppl. 1), S5 (2003).
15. Moreno Y, Nabhan JF, Solomon J, Mackenzie CD, Geary TG. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc. Natl Acad. Sci. USA 107, 20120-20125 (2010).
16. Geary TG, Woo K, McCarthy JS et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int. J. Parasitol. 40, 1-13 (2010).
17. Dreyer G, Coutinho A, Miranda D et al. Treatment of bancroftian filariasis in Recife, Brazil: A two-year comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine. Trans. R. Soc. Trop. Med. Hyg. 89, 98-102 (1995).
18. Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. Trop. Med. Int. Heath 1(4), 427-432 (1996). (Pubitemid 26264408)
19. Duke, BOL, Pacqué MC, Muñoz B, Greene BM, Taylor H.R. Viability of adult Onchocerca volvulus after six 2-weekly doses of ivermectin. Bull. World Health Organ. 69, 163-168 (1991).
20. Pfarr KM, Hoerauf AM. Antibiotics which target the Wolbachia symbionts of filarial parasites - A new strategy for control of filariasis and amelioration of pathology. Mini Rev. Med. Chem. 6, 203-210 (2006).
21. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2(Suppl. 1), S4 (2003).
22. Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989-2001: Implications for the future. Filaria J. 2(Suppl. 1), S7 (2003).
23. Bourguinat C, Kamgno J, Boussinesq M, Mackenzie C, Prichard R, Geary T. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am. J. Trop. Med. Hyg. 83, 28-32 (2010).
24. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: A two-phase epidemiological study. Lancet 369, 2021-2029 (2007). (Pubitemid 46899181)
25. Churcher TS, Pion SD, Osei-Atweneboana MY et al. Identifying suboptimal responses to ivermectin in the treatment of River Blindness. Proc. Natl Acad. Sci. USA 106, 16716-16721 (2009).
26. Bourguinat C, Ardelli BF, Pion SD et al. P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol. Biochem. Parasitol. 158, 101-111 (2008). (Pubitemid 351255520)
27. Hampshire VA. Evaluation of efficacy of heartworm preventive products at the FDA. Vet. Parasitol. 133, 191-195 (2005). (Pubitemid 41408495)
28. Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK. Correlation between loss of efficacy of macrocyclic lactone heartworm preventatives and P-glycoprotein genotype. Vet. Parasitol. 176, 374-381 (2011).
29. Orme M, Awadzi K, Edwards G, Breckenridge AM. Drug treatment of onchocerciasis. Quart. J. Med. 66, 195-201 (1988).
30. Awadzi K. Clinical picture and outcome of Serious Adverse Events in the treatment of onchocerciasis. Filaria J. 2(Suppl. 1), S6 (2003).
31. Hoerauf A. Filariasis: New drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr. Opin. Infect. Dis. 21, 673-681 (2008).
32. Turner JD, Tendongfor N, Esum M et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: A randomized controlled trial. PLoS Negl. Trop. Dis. 4, e660 (2010).
33. Bazzochi C, Mortarino M, Grandi G et al. Combined ivermectin and doxycycline treatment has microfilaricidal and adulticidal activity against Dirofilaria immitis in experimentally infected dogs. Int. J. Parasitol. 38, 1401-1410 (2008).
34. Grandi G, Quintavalla C, Mavropoulou A et al. A combination of doxycycline and ivermectin is adulticidal in dogs with naturally acquired heartworm disease (Dirofilaria immitis). Vet. Parasitol. 169, 347-351 (2010).
35. Wanji S, Tendongfor N, Nji N et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loaisis in Cameroon. Parasit. Vectors 2, 39 (2009).
36. McCall JW. The safety-net story about macrocyclic lactone heartworm preventatives: A review, an update and recommendations. Vet. Parasitol. 133, 197-206 (2005). (Pubitemid 41405852)
37. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin. Pharmacother. 6, 179-200 (2005). (Pubitemid 40305333)
38. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 376, 1175-1185 (2010).
39. Supali T, Djuardi Y, Pfarr KM et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin. Infect. Dis. 46, 1385-1393 (2008). (Pubitemid 351589938)
40. McCall JW, Genchi C, Kramer L et al. Heartworm and Wolbachia: Therapeutic implications. Vet. Parasitol. 158, 204-214 (2008).
41. Cotreau MM, Warren S, Ryan JL et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43, 1108-1115 (2003). (Pubitemid 37174442)
42. Lespine A, Martin S, Dupuy J et al. Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship. Eur. J. Pharm. Sci. 30, 84-94 (2007). (Pubitemid 44908930)
43. Bronsvoort BM, Renz A, Tchakouté V, Tanya VN, Ekale D, Trees AJ. Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle. Filaria J. 4, 4-8 (2005).
44. Conder GA, Campbell WC. Chemotherapy of nematode infections of veterinary importance, with special reference to drug resistance. Adv. Parasitol. 35, 1-84 (1995).
45. Banks BJ, Bishop BF, Evans NA et al. Avermectins and flea control: Structure-activity relationships and the selection of selamectin for development as an endectocide for companion animals. Bioorg. Med. Chem. 8, 2017-2025 (2000). (Pubitemid 30612492)
46. Scherkenback J, Jeschke J, Harder A. PF1022A and related cyclodepsipeptides - A novel class of anthelmintics. Curr. Top. Med. Chem. 2, 759-777 (2002).
47. Harder A, Schmitt-Wrede H-P, Krücken J et al. Cyclooctadepsipeptides - An anthelmintically active class of compounds exhibiting a novel mode of action. Int. J. Antimicrob. Agents 22, 318-331 (2003). (Pubitemid 37103217)
48. von Samson-Himmelstjerna G, Harder A, Sangster NC, Coles GC. Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic- resistant nematodes in sheep and cattle. Parasitology 130, 343-347 (2005). (Pubitemid 40444953)
49. Jeschke P, Iinuma K, Harder A, Schindler M, Mirakami T. Influence of the cyclooctadepsipeptides PF1022A and PF1022E natural products on the design of semi-synthetic anthelmintics such as emodepside. Parasitol. Res. 97(Suppl. 1), S11-S16 (2005). (Pubitemid 41446642)
50. Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int. J. Parasitol. 31, 1515-1522 (2001). (Pubitemid 32947006)
51. Townson S, Freeman A, Harris A, Harder A. Activity of the cyclooctadepsipeptide emodepside against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Am. J. Trop. Med. Hyg. 73(Suppl.), 93 (2005).
52. Guest M, Bull K, Walker RJ et al. The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int. J. Parasitol. 37, 1577-1588 (2007). (Pubitemid 47542465)
53. Horton J. Albendazole: A broad spectrum anthelminthic for treatment of individuals and populations. Curr. Opin. Infect. Dis. 15, 599-608 (2002). (Pubitemid 36026973)
54. Mackenzie CD, Geary TG. Flubendazole, a potentially valuable macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev. Anti Infect. Ther. 9(5), 497-501(2011).
55. Dominguez-Vasquez A, Taylor HR, Greene BM et al. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet 1(8317), 139-143 (1983). (Pubitemid 13224092)
56. Ceballos L, Elissondo M, Bruni SS, Denegri G, Alvarez L, Lanusse C. Flubendazole in cystic echinococcosis therapy: Pharmaco-parasitological evaluation in mice. Parasitol. Int. 58, 354-358 (2009).
57. Nianjun H, Cerepnalkoski L, Nwankwo JO et al. Induction of chromosomal aberrations, cytotoxicity, and morphological transformation in mammalian cells by the antiparasitic drug flubendazole and the antineoplastic drug harringtonine. Fund. Appl. Toxicol. 22, 304-313 (1994). (Pubitemid 24089175)
58. Yoshimura H. Effect of oral dosing vehicles on the developmental toxicity of flubendazole in rats. Reprod. Toxicol. 17, 377-385 (2003). (Pubitemid 36875176)
59. Spagnuolo PA, Hu, J, Hurren R et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115, 4824-4833 (2010).
60. Bronsvoort BM, Makepeace BL, Renz A et al. UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle. Parasit. Vectors 1, 18 (2008).
61. Tellez-Giron E, Ramos MC, Dufour L et al. Treatment of neurocysticercosis with flubendazole. Am. J. Trop. Med. Hyg. 33, 427-431 (1984).
62. Gavidia CM, Gonzalez AE, Barron EA et al. Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: A randomized clinical trial in naturally infected sheep. PLoS Negl. Trop. Dis 4, e616 (2010).
63. Anderson VR, Curram MP. Nitazoxanide: A review of its use in the treatment of gastrointestinal infections. Drugs 67, 1947-1967 (2007). (Pubitemid 47347408)
64. Bacon JA, Ulrich RG, Davis JP et al. Comparative in vitro effects of closantel and selected b-ketoamide anthelmintics on a gastrointestinal nematode and vertebrate liver cells. J. Vet. Pharmacol. Ther. 21, 190-198 (1998). (Pubitemid 28282791)
65. Rao RU, Huang Y, Fischer K, Fischer PU, Weil GJ. Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Exp. Parasitol. 121(1), 38-45 (2009).
66. Kaminsky R, Ducray P, Jung M et al. A new class of anthelmintics effective against drug-resistant nematodes. Nature 452, 176-180 (2008). (Pubitemid 351380246)
67. Hosking BC, Kaminsky R, Sager H, Rolfe PF, Seewald W. A pooled analysis of the efficacy of monepantel, an amino-acetonitrile derivative, against gastrointestinal nematodes of sheep. Parasitol. Res. 106, 529-532 (2010).
68. Rufener L, Keiser J, Kaminsky R, Mäser P, Nilsson D. Phylogenomics of ligand-gated ion channels predicts monepantel effect. PLoS-Pathogens 9, e1001091 (2010).
69. Lee BH, Clothier MF, Dutton FE et al. Marcfortine and paraherquamide class of anthelmintics: Discovery of PNU-141962. Curr. Top. Med. Chem. 2, 779-793 (2002).
70. Little PR, Hodges A, Watson TG, Seed JA, Maeder SJ. Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand. NZ Vet. J. 58, 121-129 (2010).
71. Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W. Tribendimidine: A promising, safe and broad-spectrum anthelmintic from China. Acta Trop. 94, 1-14 (2005). (Pubitemid 40450294)
72. Hu Y, Xiao S-H, Aroian RF. The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist. PLoS Negl. Trop. Dis. 3, e499 (2009).
73. Xue J, Xiao S-H, Xu LL, Qiang HQ. The effect of tribendimidine and its metabolites against Necator americanus in golden hamsters and Nippostrongylus brasiliensis in rats. Parasitol. Res. 106, 775-781 (2010).
74. Tripathi RP, Katiyar D, Dwivedi N, Singh BK, Pandey J. Recent development in search of antifilarial agents. Curr. Med. Chem. 13, 3319-3334 (2006). (Pubitemid 44669778)
75. Singh PK, Ajay A, Kushwaha S, Tripathi RP, Misra-Bhattacharya S. Towards novel antifilarial drugs: Challenges and recent developments. Fut. Med. Chem. 2, 251-283 (2010).
76. Woods DJ, Williams TM. The challenges of developing novel antiparasitic drugs. Inv. Neurosci. 7, 245-250 (2007). (Pubitemid 50003223)
77. Townson S, Ramirez B, Fakorede F, Mouries M-A, Nwaka S. Challenges in drug discovery for novel antifilarials. Expert Opin. Drug. Discov. 2(Suppl. 1), S63-S73 (2007). The paths for antifilarial discovery are clearly elaborated in this article and serve as an excellent introduction to the difficulties encountered in this field. (Pubitemid 47616031)
78. Thompson DP, Klein RD, Geary TG. Prospects for rational approaches to anthelmintic discovery. Parasitol. 113, S217-S238 (1996). (Pubitemid 27095167)
79. Geary TG, Thompson DP, Klein RD. Mechanism-based screening: Discovery of the next generation of anthelmintics depends upon more basic research. Int. J. Parasitol. 29, 105-112 (1999). (Pubitemid 29042251)
80. Geary TG, Thompson DP. Caenorhabditis elegans: How good a model for veterinary parasites? Vet. Parasitol. 101, 371-386 (2001). (Pubitemid 33052460)
81. Burns AR, Wallace IM, Wildenhain J et al. A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat. Chem. Biol. 6, 549-557 (2010).
82. Ruiz-Lancheros E, Viau C, Walter TN, Francis, A, Geary TG. Activity of novel nicotinic anthelmintics in cut preparations of Caenorhabditis elegans. Int. J. Parasitol. 41, 455-461 (2011).
83. Woods DJ, Lauret C, Geary TG. Anthelmintic discovery and development in the animal health industry. Expert Opin. Drug. Discov. 2(Suppl. 1), S25-S33 (2007). (Pubitemid 47611475)
84. Geary TG, Woods DJ, Williams T, Nwaka S. Target identification and mechanism-based screening for anthelmintics: Application of veterinary antiparasitic research programmes to search for new antiparasitic drugs for human indications. In:Drug Discovery in Infectious Diseases Selzer PM (Ed.). Wiley-VCH, Weinheim, Germany, 1-16 (2009).
85. McCarter JP. Genome filtering: An approach to discovering novel antiparasitics. Trends Parasitol. 20, 462-468 (2004). (Pubitemid 39195055)
86. Kumar S, Chaudhary K, Foster JM et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS ONE 11, e1189 (2007).
87. Agüero F, Al-Lazikani, B, Aslett M et al. Genomic-scale prioritization of drug targets: The TDR Targets database. Nat. Rev. Drug Discov. 7, 900-907 (2008).
88. Crowther GJ, Shanmugam D, Carmona SJ et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 4, e804 (2010).
89. Behm CA, Bendig MM, McCarter JP, Sluder AE. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. 21, 97-100 (2005). (Pubitemid 40269770)
90. Knox DP, Geldhof P, Visser A, Britton C. RNA interference in parasitic nematodes of animals: A reality check. Trends Parasitol. 23, 105-107 (2007).
91. Eberhard ML, Dickerson JW, Tsang VCW et al. Onchocerca volvulus: Parasitological and serological responses in experimentally infected chimpanzees and mangabey monkeys. Exp. Parasitol. 80, 454-462 (1995).
92. Dube A, Murthy PK, Puri SK, Misra-Bhattacharya S. Presbytis entellus: A primate model for parasitic disease research. Trends Parasitol. 20, 358-360 (2004). (Pubitemid 38916524)
93. Allen JE, Adjei O, Bain O et al. Of mice, cattle, and humans: The immunology and treatment of river blindness. PLoS Negl. Trop. Dis. 2, e217 (2008).
94. Hewitson JP, Harcus YM, Curwen RS et al. The secretome of the filarial parasite, Brugia malayi: Proteomic profile of adult excretory-secretory products. Mol. Biochem. Parasitol. 160, 8-21 (2008). (Pubitemid 351694354)
95. Moreno Y, Geary TG. Stage- And gender-specific proteomic analysis of Brugia malayi excretory-secretory products. PLoS Negl. Trop. Dis. 2, e326 (2008).
96. Bennuru S, Semnani R, Meng Z, Ribeiro JM, Veenstra TD, Nutman TB. Brugia malayi excreted/secreted proteins at the host/parasite interface: Stage- And gender-specific proteomic profiling. PLoS Negl. Trop. Dis. 3, e410 (2009).
97. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nature Drug Disc. 5, 941-955 (2006). (Pubitemid 44660607)
98. Hudson A, Nwaka S. The concept paper on the Helminth Drug Initiative. Onchocerciasis/lymphatic filariasis and schistosomiasis: Opportunities and challenges for the discovery of new drugs/diagnostics. Exp. Opin. Drug Discov. 2(Suppl. 1), S3-S7 (2007). (Pubitemid 47611474)
99. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases - criteria for lead progression. PLoS Negl. Trop. Dis. 3, e440 (2009).